Cargando…
Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease
Gaucher disease (GD) is a heritable storage disorder caused by functional defects of the lysosomal acid β-glucosidase and the accumulation of glucosylceramide within macrophages, resulting in multiple organ dysfunction. There are three commercially available enzyme replacement therapy (ERT) products...
Autores principales: | Gupta, Punita, Pastores, Gregory M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774592/ https://www.ncbi.nlm.nih.gov/pubmed/29388611 http://dx.doi.org/10.2147/PHMT.S93634 |
Ejemplares similares
-
Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2018) -
Breastfeeding in patients with Gaucher disease: Is taliglucerase alfa safe?
por: Paskulin, Livia, et al.
Publicado: (2019) -
An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease
por: Hollak, Carla EM
Publicado: (2012) -
Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease
por: Abbas, Richat, et al.
Publicado: (2015) -
Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa
por: Zimran, Ari, et al.
Publicado: (2018)